PhRMA, top De­moc­rats urge Supreme Court to take up abor­tion pill case

It’s a rar­i­ty these days to see the top phar­ma in­dus­try lob­by­ing group join Sen­ate and House De­mo­c­rat lead­ers and ar­gue the same side of any is­sue, but that’s the case with pe­ti­tion­ing the Supreme Court to take up a case on the abor­tion pill mifepri­s­tone. The case could have rip­ple ef­fects for all drug ap­provals.

PhRMA makes clear in an am­i­cus brief filed last Thurs­day that the Fifth Cir­cuit’s de­ci­sion in Au­gust to re­strict the use of mifepri­s­tone and its gener­ic ver­sions un­der the con­di­tions for use that ex­ist­ed in 2016, be­fore the FDA loos­ened some of the reg­u­la­tions, could lead to neg­a­tive con­se­quences for the phar­ma in­dus­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER